• Mononuclear cells for DC production were obtained after leukapheresis
• After thawing, cells were placed in X-VIVO-15 medium in tissue culture flasks at a concentration of 1.3 to 1.7×106 cells/cm2 of available culturing surface
• After 2 hours of culture, nonadherent cells were removed and the flask were recharged with X-VIVO-15 medium supplemented with 5ng/mL GMC- SF and 5ng/mL IL-4
• The flask was incubated for 48 hours at which time additional cytokine- supplemented medium was added to the flask, incubated for additional 72 hours
• After the completion of incubation, the nonadherent and loosely adherent
cells were collected and used for 2hour infection with Adp53 at a viral particle to all ration of 15,000:1.
Patients treated with EBRT combined with Intratumorally injection of DC. Radiation was delivered 5 days a week. DC 107 cells were injected IT 3 times on the 2nd, 3rd and 4th Friday during the course of radiation.
• No significant (>=grade2) toxicity was observed during combination of EBRT/DC treatment
• 12 patients (70.6%) had no evidence of the disease for at least 1 year after the start of the treatment.
• Among those 12, 6 patients are disease free for more than 2 years and 4 patients for more than 3 years.
• 9 out of 17 patients (52.9%) demonstrated a positive tumor-specific immune response which lasted from 11-42 weeks.
Combination of Intratumorally DC administration with EBRT was safe and resulted in induction of antitumor immune responses and could be a promising method for the treatment of patients with Soft Tissue Sarcoma (STS).
Article Reference link: click here
Scientific article publishing date: 11/23/2015
Immucura identifier BSC21_323EN